Ownership and insider activity for BioCardia, Inc. (BCDA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions.
Price
| Price | $1.25 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.4M | $12.7M | $5.4M | $5.6M | $21.4M | $12.9M | $7.4M | $1.1M | $2.4M | $2.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $74000 | $95000 | $274000 | $147000 | $232000 | $147000 | $201000 | $63000 | 0 | $20000 |
| Inventory | $135000 | $191000 | $141000 | $4000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $21.9M | $13.3M | $6.2M | $6.4M | $22.7M | $13.5M | $7.9M | $1.5M | $2.6M | $2.7M |
| Property, Plant & Equipment | $111000 | $169000 | $145000 | $1.2M | $712000 | $2.1M | $1.8M | $1.4M | $931000 | $510000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $22.1M | $13.5M | $6.4M | $7.7M | $23.4M | $15.7M | $9.8M | $3.0M | $3.7M | $3.4M |
| Accounts Payable | $525000 | $902000 | $743000 | $914000 | $746000 | $507000 | $683000 | $890000 | $385000 | $641000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.4M | $2.3M | $2.5M | $4.0M | $4.2M | $3.7M | $3.6M | $3.6M | $2.3M | $2.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.5M | $2.4M | $2.6M | $5.3M | $4.2M | $5.3M | $4.9M | $4.6M | $2.9M | $2.5M |
| Retained Earnings | -$60.1M | -$72.5M | -$86.4M | -$101.1M | -$116.1M | -$128.7M | -$140.6M | -$152.2M | -$160.1M | -$168.3M |
| Total Equity | $20.6M | $11.1M | $3.8M | $2.4M | $19.2M | $10.4M | $4.9M | -$1.6M | $837000 | $895000 |
| Total Debt | 0 | 0 | 0 | $1.1M | $614000 | $1.9M | $1.6M | $1.3M | $951000 | $528000 |
| Net Debt | -$21.4M | -$12.7M | -$5.4M | -$4.4M | -$20.8M | -$11.0M | -$5.7M | $212000 | -$1.4M | -$2.0M |
| Working Capital | $20.5M | $11.0M | $3.7M | $2.4M | $18.4M | $9.8M | $4.3M | -$2.1M | $301000 | $300000 |
Financial Health
| Debt / Equity | 0.59 |
| Current Ratio | 1.12 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -74.97 |
Profitability
| Return on Equity | -919.33% |
| Return on Invested Capital | -581.73% |
| Return on Assets | -241.08% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · ALZN · APRE · APVO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of BCDA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks